Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Egile Nagusiak: V. I. Ignatyeva (Egilea), S. V. Moiseev (Egilea), N. M. Bulanov (Egilea), E. A. Karovajkina (Egilea), A S. Moiseev (Egilea)
• Formatua: Liburua
• Argitaratua: IRBIS LLC, 2019-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...